Brian Levy

Company: InflammX Therapeutics

Job title: Chief Executive Officer

Seminars:

Immune Surveillance Upstream of NLRP3 Pathway: Clinical Insights on Diabetes & Retinal Disease 9:30 am

Showcasing Xiflam (oral drug) targeting a cytoplasmic loop to close pathologically open Cx43 channels and shut down a priming signal for NLRP3 assembly Unravelling the mechanisms of inhibiting a perpetuated inflammatory response without compromising patients’ immunity Revealing updates on the ongoing Phase II clinical trial for intermediate AMD with QD dosed Xiflam (biomarkers, endpoints, and…Read more

day: Conference Day Two AM